Hosted on MSN

GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares

(Bloomberg) -- GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around the drug pipeline. The British drugmaker boosted its 2031 ...

GSK Still Has Room To Run Despite Vaccine Cyclicality

GSK is shifting to specialty growth (HIV, oncology, asthma) with key launches and a deep late-stage pipeline—still ...
Nasdaq

GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...
FiercePharma

With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once again. GSK now expects to generate more than 40 billion pound sterling ($50 ...
Investopedia

GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Seeking Alpha

GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025

GSK specialty medicines grew YoY in Q1 2025. In fact, it's now their main profit engine, offsetting the weakness in their vaccine segment. Similarly, the company's oncology, HIV, and respiratory ...